alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 01-30808 Conference Calendar

ANGELA M. BOUTTE, Plaintiff-Appellant,

versus GEORGE W. BUSH, Jr., President of the United States; RICHARD B. CHENEY, Vice President of the United States; MARY LANDRIEU, U.S. Senator; MARC H. MORIAL, Mayor; CITY OF NEW ORLEANS; MICHELLE M. MORIAL; WWL TELEVISION STATION; T. LAMAR TEAFORD, Dr.; LAKELAND MEDICAL CENTER; KAMRAN ZAHERI, M.D.; TENET HEALTH SYSTEM MEMORIAL MEDICAL CENTER, INC.; UNIDENTIFIED PARTIES, Defendants-Appellees.

-------------------- Appeal from the United States District Court for the Eastern District of Louisiana

USDC No. 01-CV-661-R

-------------------- October 25, 2001 Before WIENER, BENAVIDES, and DENNIS, Circuit Judges.
PER CURIAM: Angela Boutte has filed a motion to proceed in forma pauperis (IFP) and a motion to expedite her appeal of the district court’s dismissal of her civil complaint as frivolous. A district court may deny a motion for leave to appeal IFP by certifying that the appeal is not taken in good faith and by providing written reasons for the certification. See Baugh v. Taylor , 117 F.3d 197, 202 (5th Cir. 1997); 28 U.S.C. § 1915(a)(3); Fed. R. App. P. 24(a). The appellant may challenge the district court's certification decision by filing in thisO R D E R No. 01-30808 - 2 - court a motion for leave to proceed IFP. Id . at 202; Fed. R. App. P. 24(a)(5). The motion, however, "must be directed solely to the trial court's reasons for the certification decision." See Baugh , 117 F.3d at 202. Boutte’s motion does not challenge the district court’s certification that the appeal was not taken in good faith, as is required. It is therefore DENIED. If the merits of the appeal are "inextricably intertwined with the certification decision," we may determine both issues. Baugh , 117 F.3d at 202. Our inquiry into an appellant's good faith" is limited to whether the appeal involves `legal points arguable on their merits (and therefore not frivolous).'" Howard v. King , 707 F.2d 215, 220 (5th Cir. 1983) (citation omitted). Probable success on the merits is not required. Id

. Boutte has failed to show that her appeal involves nonfrivolous legal issues. Her claims are “inextricably intertwined” with the district court’s certification decision, and, therefore, we dismiss the appeal as frivolous in the interest of judicial economy. See Baugh , 117 F.3d at 202; 5th Cir. R. 42.2. Boutte’s motion to expedite appeal is DENIED as
moot. Motion for IFP status DENIED; motion to expedite appeal DENIED; all other motions are DENIED; appeal DISMISSED.
From: creach64@gmail.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 3:16:21 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Loren Kraus

Salina, KS 67401
No. 61479.

#### Marconi Instruments, Ltd. *v.*United States,

protest 274507-K (New York).

Opinion by

Lawrence, J.

In accordance with stipulation of counsel that the merchandise consists of klystron tubes the same in all material respects as those the subject of *Marconi Instruments, Ltd.*v. *United States*(38 Cust. Ct. 311, C. D. 1880), the claim of the plaintiff was sustained.
SUPPLEMENT TO THE PROSPECTUS

Effective February 19, 1996, existing shares of United Gold & Government Fund,
Inc. will be reclassified as Class A shares and the Fund will begin to offer
Class Y shares.  Class Y shares will be offered through a Prospectus separate
from the Class A Prospectus to certain institutional investors and will not be
subject to a sales charge, redemption fee or Rule 12b-1 fee.  Additional
information about Class Y shares may be obtained by calling 913-236-2000 or by
writing to Waddell & Reed, Inc. at the address on the inside back cover of the
Prospectus to which this Supplement is attached.

This Supplement is to be attached to the cover page of the Prospectus of United
Gold & Government Fund, Inc. dated March 31, 1995.

This Supplement is dated January 3, 1996.

NUS1013

<PAGE>
SUPPLEMENT TO THE STATEMENT OF ADDITIONAL INFORMATION

Effective February 19, 1996, existing shares of United Gold & Government Fund,
Inc. will be reclassified as Class A shares and the Fund will begin to offer
Class Y shares.  Class Y shares will be offered through a Prospectus separate
from the Class A Prospectus to certain institutional investors and will not be
subject to a sales charge, redemption fee or Rule 12b-1 fee.  Class Y shares
will have a different Shareholder Servicing fee.  Additional information about
Class Y shares may be obtained by calling 913-236-2000 or by writing to Waddell
& Reed, Inc. at the address on the cover of the Statement of Additional
Information to which this Supplement is attached.

This Supplement is to be attached to the cover page of the Statement of
Additional Information of United Gold & Government Fund, Inc. dated March 31,
1995.

This Supplement is dated January 3, 1996.
#### UNITED STATES of America, Plaintiff-Appellee, v. Marcial CABADA-NAVARRETE, Defendant-Appellant.

No. 00-10246.

D.C. No. CR-99-00035-RGS.

United States Court of Appeals, Ninth Circuit.

Submitted June 11, 2001 *.

Decided June 21, 2001.

Before O’SCANNLAIN, SILVERMAN, and GOULD, Circuit Judges.

*

 The panel unanimously finds this case suitable for decision without oral argument. *See*Fed. R.App. P. 34(a)(2).

MEMORANDUM **

Marcial Cabada-Navarrete appeals the 60-month sentence imposed by the district court following his guilty-plea conviction for illegal reentry after deportation, in violation of 8 U.S.C. § 1326(a). We have jurisdiction pursuant to 28 U.S.C. § 1291, and we affirm.

Cabada-Navarrete contends that *Apprendi v. New Jersey,*530 U.S. 466, 120 S.Ct. 2348, 147 L.Ed.2d 435 (2000), requires a remand to the district court because a prior aggravated felony conviction should be a fact determined by a jury and proven beyond a reasonable doubt. This contention is foreclosed by *United States v. Pacheco-Zepeda,*234 F.3d 411 (9th Cir.2000), ce*rt. denied,*— U.S. -, 121 S.Ct. 1503, 149 L.Ed.2d 388 (2001).

Cabada-Navarrete also contends that counsel was ineffective for failing to raise and preserve the *Apprendi*issue before the district court. However, given *Pacheco-Zepeda,*we reject Cabada-Navarrete’s contention because he has failed to demonstrate ineffective assistance of counsel from counsel’s failure to argue that the prior aggravated felony conviction should have been determined by a jury. *See Shah v. United States,*878 F.2d 1156, 1162 (9th Cir.1989) (concluding that failure to raise a meritless legal argument does not constitute ineffective assistance of counsel); *see also United States v. Rivera-Sanchez,*222 F.3d 1057, 1060 (9th Cir.2000) (holding that where the record is sufficiently developed to permit review and determination, an ineffective assistance claim may be reviewed on direct appeal).

Cabada-Navarrete also contends that his prior drug possession convictions combined do not qualify as aggravated felony convictions for purposes of the 16-level sentencing enhancement under U.S.S.G. § 2L1.2(b)(l)(A)(1999). We previously held that a second drug possession conviction qualifies as an aggravated felony for purposes of 8 U.S.C. § 1101(a)(43). *United States v. Garciar-Olmedo,*112 F.3d 399, 402 (9th Cir.1997). We conclude the district court did not err by considering Cabada-Navarrete’s prior possession convictions to increase his offense level by 16 points under U.S.S.G. § 2L1.2(b)(l)(A).

AFFIRMED.

**

 This disposition is not appropriate for publication and may not be cited to or by the courts of this circuit except as may be provided by 9th Cir. R. 36-3.
```

[Federal Register Volume 88, Number 185 (Tuesday, September 26, 2023)]
[Notices]
[Page 66015]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20877]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIHAI75N93023R00003: Pre-clinical 
Models of Infectious Diseases--Task Area A.
    Date: October 27-November 1, 2023.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E70A, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Annie Walker-Abbey, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E70A, 
Rockville, MD 20852, 240-627-3390, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: September 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20877 Filed 9-25-23; 8:45 am]
BILLING CODE 4140-01-P
```
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 280 Introduced in House (IH)]

110th CONGRESS
  1st Session
H. RES. 280

 Congratulating Thomas Jefferson High School on winning the 2006-2007 
       PSAL New York City A-League Girls Basketball Championship.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 27, 2007

Mr. Towns submitted the following resolution; which was referred to the 
                    Committee on Education and Labor

_______________________________________________________________________

                               RESOLUTION

 
 Congratulating Thomas Jefferson High School on winning the 2006-2007 
       PSAL New York City A-League Girls Basketball Championship.

Whereas Thomas Jefferson High School of Brooklyn, New York, defeated Newton High 
        School of Elmhurst, New York, to win the 2006-2007 PSAL New York City A-
        League Girls Basketball Championship;
Whereas the Thomas Jefferson High School girls basketball team finished the 
        2006-2007 season with a 17-1 overall record; and
Whereas the Thomas Jefferson High School girls basketball team is the first 
        girls basketball team from Brooklyn, New York, to make it to the State 
        playoffs: Now, therefore, be it
    Resolved,  That the House of Representatives congratulates Mr. 
Michael Alexander, the principal of Thomas Jefferson High School, Mr. 
Calvin Young, the head coach of the Thomas Jefferson High School girls 
basketball team, and the Thomas Jefferson High School girls basketball 
team upon winning the 2006-2007 PSAL New York City A-League Girls 
Basketball Championship.
                                 <all>
```
|   |   |
|--------|--------|

**Filed      Pursuant To Rule 433, Registration No. 333-124310**
** **

**$1,000,000,000**

**CATERPILLAR      FINANCIAL SERVICES CORPORATION**

| **For                the Period: 5/14/2007 to 5/21/2007** |
|-----------------------------------------------------------|
| **Coupon**                                                | **Interest** | **Maturity** | **Callable** | **Survivor's****Option** | **Price****1** | **Yield****2** | **Moody's** | **S&P** | **CUSIP** |
| 4.900%                                                    | Semi-Annual(†††) | 5/15/09 | NO | YES§  | 100.00 | 4.900% | A2 | A | 14912HCY4 |
| 5.000%                                                    | Monthly(†) | 5/15/12 | 5/15/09*  | YES§  | 100.00 | 5.052% | A2 | A | 14912HCZ1 |
| 5.600%                                                    | Monthly(†) | 5/15/22 | 5/15/10*  | YES§  | 100.00 | 5.666% | A2 | A | 14912HDA5 |
| 5.750%                                                    | Semi-Annual(†††) | 5/15/27 | 5/15/11***  | YES§  | 100.00 | 5.750% | A2 | A | 14912HDB3 |

*All      offerings are subject to prior sale.*
Exhibit
32.2

MARINA
BIOTECH, INC.

CERTIFICATION
PURSUANT TO

18
U.S.C. SECTION 1350

AS
ADOPTED PURSUANT TO

SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002



In
connection with this Annual Report on Form 10-K/A of Marina Biotech, Inc. (the “Company”) for the year ended
December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the
undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:



|1. | The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                  
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                            
|2. | The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operation
    of the Company.



|Date:  | April
    30, 2018                                                                         | 
|------ | ------------------------------------------------------------------------------------------ | 
|       |                                                                                            | 
|By:    | /s/
    Amit Shah                                                                          | 
|Name:  | Amit
    Shah                                                                              | 
|Title: | Chief
    Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
Before the Second Division,

October 21, 1968

No. P68/441.

protests 317496-K, etc. (New York).

No. P68/442.

protest 61/6186-12080 (Chicago).

#### Herbert A. H. Behrens, Inc., et al. *v.*United States, Gallagher & Ascher Co. *v.*United States,

Rao, C. J.

In accordance with stipulation of counsel that the merchandise covered by the foregoing protests consists of bicycles, with or without tires having wheels in diameter (measured to the outer circumference of the tire) over 25 inches, weighing less than 36 pounds complete without accessories, and not designed for use with tires having a cross-sectional diameter exceeding 1% inches and that the merchandise and issues herein are similar in all material respects to those the subject of *United States*v. *Schmidt Pritchard &*Co., *Mangano Cycles Co.*(47 CCPA 152, C.A.D. 750), the claim of the plaintiffs was sustained.
No. 69621.

#### P. L. Thomas & Co., Inc. *v.*United States,

protests 65/660 and 65/3780 (New York).

Opinion by

Nichols, J.

In accordance with stipulation of counsel that the merchandise consists of coffee stirrers similar in all material respects to those the subject of Abstract 67164, the claim of the plaintiff was sustained.
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Page 65181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20493]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIHAI75N93023R00003: Pre-clinical 
Models of Infectious Diseases--Task Area B.
    Date: October 20-23, 2023.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E70A, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Annie Walker-Abbey, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E70A, 
Rockville, MD 20852, 240-627-3390, <a href="/cdn-cgi/l/email-protection#5a3b3b38383f231a34333b333e74343332743d352c"><span class="__cf_email__" data-cfemail="b5d4d4d7d7d0ccf5dbdcd4dcd19bdbdcdd9bd2dac3">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: September 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20493 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
From: SAMYU_LA@YAHOO.COM

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 12:18:11 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

SAM YU

, CA91030
No. 69792.

protests 63/8335-13422, etc. (Chicago).

#### International Expediters, Inc., et al. *v.*United States,

Opinion by

Ford, J.

In accordance with stipulation of counsel that the merchandise consists of earphones similar in all material respects to those the subject of Abstract 69019, the claim of the plaintiff was sustained.
EXHIBIT 13.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Global Ship
Lease, Inc. (the Company) on Form 20-F for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the Form 20-F), I Ian J. Webber, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Form 20-F fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------

Dated: May 18, 2011



|    |  |                              
|--- |  | -----------------------------
|By: |  | /s/ Ian J. Webber            
|    |  | Ian J. Webber                
|    |  | Chief Executive Officer      
|    |  | (Principal Executive Officer)